{"id":44119,"date":"2025-10-22T20:33:19","date_gmt":"2025-10-22T12:33:19","guid":{"rendered":"https:\/\/flcube.com\/?p=44119"},"modified":"2025-10-22T20:33:20","modified_gmt":"2025-10-22T12:33:20","slug":"rani-therapeutics-and-chugai-forge-1-085-billion-collaboration-deal-for-innovative-oral-therapeutic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44119","title":{"rendered":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic"},"content":{"rendered":"\n<p><strong>Rani Therapeutics Holdings, Inc.<\/strong> today announced a comprehensive <strong>Collaboration and License Agreement<\/strong> with Japan\u2019s <strong>Chugai Pharmaceutical Co., Ltd.<\/strong> to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary <strong>RaniPill<\/strong> delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\"><strong>Deal Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Up\u2011front Payment<\/strong><\/td><td><strong>$10\u202fmillion<\/strong> to Rani<\/td><\/tr><tr><td><strong>Success\u2011Based Technology Transfer<\/strong><\/td><td>Up to <strong>$75\u202fmillion<\/strong> contingent on milestones<\/td><\/tr><tr><td><strong>Sales\u2011Based Milestones<\/strong><\/td><td>Up to <strong>$100\u202fmillion<\/strong> linked to commercial performance<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td>Single\u2011digit royalty on sales after commercialization<\/td><\/tr><tr><td><strong>Option for Additional Targets<\/strong><\/td><td>Up to <strong>5<\/strong> more drug targets under similar terms<\/td><\/tr><tr><td><strong>Maximum Deal Value<\/strong><\/td><td><strong>$1.085\u202fbillion<\/strong> if fully exercised<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The first target focuses on a rare\u2011disease antibody, with the possibility of expanding the partnership across multiple therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-impact\"><strong>Financial &amp; Operational Impact<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PIPE Financing<\/strong> \u2013 Rani has closed a <strong>Private Investment in Public Equity (PIPE)<\/strong> transaction led by <strong>Samsara BioCapital<\/strong>. Gross proceeds of <strong>$60.3\u202fmillion<\/strong> are expected, with net proceeds (after fees) projected to fund operations through <strong>2028<\/strong>.<\/li>\n\n\n\n<li><strong>Chugai Up\u2011front &amp; Milestone Funds<\/strong> \u2013 Combined with the <strong>$10\u202fmillion<\/strong> upfront and <strong>$18\u202fmillion<\/strong> anticipated technology\u2011transfer milestones, Rani will have sufficient liquidity to support R&amp;D, regulatory, and commercialization activities for the first drug target.<\/li>\n\n\n\n<li><strong>Long\u2011Term Growth<\/strong> \u2013 The collaboration positions Rani to expand its oral delivery platform into the rare\u2011disease space, while Chugai gains access to a proven delivery system that can reduce hematologic toxicity and improve patient adherence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\"><strong>Strategic Significance<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RaniPill Advantage<\/strong> \u2013 The platform delivers small\u2011molecule therapeutics orally, offering a first\u2011in\u2011class approach to rare\u2011disease treatment.<\/li>\n\n\n\n<li><strong>Dual\u2011Innovation<\/strong> \u2013 Combining Rani\u2019s delivery technology with Chugai\u2019s antibody expertise creates a synergistic product that could outperform existing parenteral therapies.<\/li>\n\n\n\n<li><strong>Scalable Partnership<\/strong> \u2013 The option to extend the collaboration to up to five additional targets provides a clear pathway for portfolio expansion and revenue diversification.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Rani-Therapeutics-Announces-up-to-1.085-Billion-Collaboration-with-Chugai-Pharmaceutical-Co.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co.\"><\/object><a id=\"wp-block-file--media-bd23682f-b608-460a-ab3e-b5ccd95cc6b0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Rani-Therapeutics-Announces-up-to-1.085-Billion-Collaboration-with-Chugai-Pharmaceutical-Co.pdf\">Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Rani-Therapeutics-Announces-up-to-1.085-Billion-Collaboration-with-Chugai-Pharmaceutical-Co.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bd23682f-b608-460a-ab3e-b5ccd95cc6b0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[382,4409],"class_list":["post-44119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chugai-pharmaceutical","tag-rani-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44119\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic\" \/>\n<meta property=\"og:description\" content=\"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44119\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:33:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T12:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic\",\"datePublished\":\"2025-10-22T12:33:19+00:00\",\"dateModified\":\"2025-10-22T12:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2208.webp\",\"keywords\":[\"Chugai Pharmaceutical\",\"Rani Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44119#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44119\",\"name\":\"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2208.webp\",\"datePublished\":\"2025-10-22T12:33:19+00:00\",\"dateModified\":\"2025-10-22T12:33:20+00:00\",\"description\":\"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44119\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2208.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2208.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44119#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic - Insight, China&#039;s Pharmaceutical Industry","description":"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44119","og_locale":"en_US","og_type":"article","og_title":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic","og_description":"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.","og_url":"https:\/\/flcube.com\/?p=44119","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T12:33:19+00:00","article_modified_time":"2025-10-22T12:33:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44119#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44119"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic","datePublished":"2025-10-22T12:33:19+00:00","dateModified":"2025-10-22T12:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44119"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","keywords":["Chugai Pharmaceutical","Rani Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44119#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44119","url":"https:\/\/flcube.com\/?p=44119","name":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44119#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","datePublished":"2025-10-22T12:33:19+00:00","dateModified":"2025-10-22T12:33:20+00:00","description":"Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan\u2019s Chugai Pharmaceutical Co., Ltd. to jointly develop and commercialize an oral drug that couples Rani\u2019s proprietary RaniPill delivery platform with a rare\u2011disease antibody in Chugai\u2019s pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44119#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44119"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44119#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","width":1080,"height":608,"caption":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44119#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rani Therapeutics and Chugai Forge $1.085\u202fBillion Collaboration Deal for Innovative Oral Therapeutic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2208.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44119"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44119\/revisions"}],"predecessor-version":[{"id":44124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44119\/revisions\/44124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44123"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}